Drugs Xagena
The European Commission has approved Dupixent ( Dupilumab ) for use in adults and adolescents 12 years and older as an addon maintenance treatment for severe asthma with type 2 inflammation characteri ...
The FDA ( U.S. Food and Drug Administration ) has approved Dupixent ( Dupilumab ) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis ( CRSwNP ) in adults whose disease i ...
The European Commission ( EC ) has expanded the marketing authorization for Dupixent ( Dupilumab ) in the European Union ( EU ) to treat eosinophilic esophagitis ( EoE ) in adults and adolescents 12 y ...
